Akari Therapeutics Taps RNA Splicing Leader Olga Anczukow for PH1 ADC Strategy
Akari Therapeutics appointed Olga Anczukow, Ph.D., a leading RNA splicing and cancer biology authority, to its Scientific Advisory Board to guide its novel PH1 antibody drug conjugate program. Dr. Anczukow’s translational research and biomarker expertise will support advancement of lead candidate AKTX-101 and ADC candidate AKTX-102 toward IND-enabling studies.
1. Appointment of RNA Biology Leader
On February 23, 2026, Akari Therapeutics announced the appointment of Olga Anczukow, Ph.D., to its Scientific Advisory Board, bringing a leading authority in RNA splicing and cancer biology to support its antibody drug conjugate programs.
2. Dr. Anczukow's Extensive Academic Background
Dr. Anczukow serves as an Associate Professor at The Jackson Laboratory for Genomic Medicine and Co-Program Leader at its Cancer Center, where she investigates how alternative RNA splicing drives tumor initiation, progression, metastasis and therapeutic resistance.
3. Strategic Implications for PH1 ADC Pipeline
Her addition is expected to accelerate development of Akari’s novel PH1 spliceosome-modulating payload in ADC candidates AKTX-101 and AKTX-102, bolstering IND-enabling studies with biomarkers and translational strategies toward a first-in-human trial by late 2026.